NCT04281927

Brief Summary

A single center prospective case-control study to evaluate ability of a wearable to differentiate between atrial fibrillation (AF) and sinus rhythm (SR).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
435

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 6, 2019

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 15, 2019

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 15, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 24, 2020

Completed
Last Updated

February 10, 2021

Status Verified

February 1, 2021

Enrollment Period

8 months

First QC Date

January 15, 2020

Last Update Submit

February 5, 2021

Conditions

Keywords

wearableelectrocardiographyphotoplethysmography

Outcome Measures

Primary Outcomes (1)

  • Diagnostic accuracy of a wearable system for atrial fibrillation detection

    The wearable system comprises of two integrated components: a photoplethysmography (PPG) and a 6-lead ECG of the device. It works as described below. First, an automatic PPG algorithm will indicate whether atrial fibrillation is suspected. The rhythm assessment of PPG algorithm is based on pulse regularity. Next, a 6-lead ECG is acquired by the wearable. The rhythm assessment of ECG is based on P waves and regularity of QRS complexes. A diagnosis is made by independent cardiologists. The conclusion of a whole system comprising of both described methods will be compared with a gold standard multi-lead Holter ECG. This standard ECG is also evaluated by independent cardiologists.

    PPG will be assessed in 2 minutes. ECG will be assessed in up to 10 months.

Secondary Outcomes (2)

  • Diagnostic accuracy of PPG algorithm of the wearable for atrial fibrillation detection

    2 minutes.

  • Diagnostic accuracy of a 6-lead ECG of the wearable for atrial fibrillation detection

    Up to 10 months.

Study Arms (3)

Atrial fibrillation

Patients with presumed atrial fibrillation will undergo monitoring with the device and Holter ECG.

Device: Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)

Sinus rhythm

Patients with presumed sinus rhythm will undergo monitoring with the device and Holter ECG.

Device: Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)

Sinus rhythm and frequent extrasystoles

Patients with presumed sinus rhythm and frequent extrasystoles will undergo monitoring with the device and Holter ECG.

Device: Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)

Interventions

Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).

Atrial fibrillationSinus rhythmSinus rhythm and frequent extrasystoles

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Participants of defined groups will be enrolled in Vilnius University Hospital Santaros Clinics.

You may qualify if:

  • Participants with current ECG-based diagnosis of atrial fibrillation, sinus rhythm or sinus rhythm with frequent (at least once in 2 minutes) premature atrial or ventricular contractions.
  • Age is between 18 - 99.

You may not qualify if:

  • Participants who refuse to sign an informed consent.
  • Participants with atrial fibrillation who are currently in a paced rhythm.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vilnius University

Vilnius, Lithuania

Location

MeSH Terms

Conditions

Atrial Fibrillation

Interventions

Electrocardiography, Ambulatory

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ElectrocardiographyHeart Function TestsDiagnostic Techniques, CardiovascularDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosisMonitoring, AmbulatoryMonitoring, Physiologic

Study Officials

  • Audrius Aidietis, Prof. PhD

    Vilnius University

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 15, 2020

First Posted

February 24, 2020

Study Start

March 6, 2019

Primary Completion

November 15, 2019

Study Completion

November 15, 2019

Last Updated

February 10, 2021

Record last verified: 2021-02

Locations